Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
Sponsor: Neurosterix
Summary
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Official title: A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
73
Start Date
2025-10-03
Completion Date
2026-05
Last Updated
2026-01-15
Healthy Volunteers
Yes
Interventions
NTX-253
Oral Capsule
Placebo
Oral capsule
Locations (1)
Collaborative Neuroscience Research, LLC - CenExel
Los Alamitos, California, United States